Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
Oncology·MeSH: Neoplasms
Prevalence
41.9 / 100K
Incidence
7.4 / 100K/yr
1 drug in development·1 company·3 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| ndv-01 | RELMADA THERAPEUTICS, INC. (RLMD) |
Frequently asked questions
How many drugs are in development for Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)?
BioSniper tracks 1 drug in development for Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) across 1 company.
How many clinical trials target Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)?
There are 3 clinical trials targeting Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) tracked by BioSniper.
What is the prevalence of Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)?
The estimated prevalence of Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) is approximately 41.9 per 100,000 population.
Deep-dive into Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis